Gilead Sciences

Assembly Biosciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biotherapeutics targeting microbiome-related diseases. The company is advancing a pipeline of drug candidates aimed at improving cure rates for chronic HBV by inhibiting various steps in the viral lifecycle. Its microbiome program features a comprehensive platform for strain identification, isolation, and growth under Good Manufacturing Practices, complemented by a patented delivery system known as GEMICEL, which facilitates targeted oral delivery of therapies to the lower gastrointestinal tract. Key product candidates include ABI-H0731, currently in Phase 2a clinical trials for HBV, and additional candidates under development for conditions such as Crohn’s disease, irritable bowel syndrome, and oncology. Assembly also collaborates with Allergan Pharmaceuticals and Door Pharmaceuticals to enhance its research and development efforts. The company was formerly known as Ventrus Biosciences, Inc. before rebranding in June 2014.

The Children’s Inn at NIH enhances the opportunities for groundbreaking medical discoveries by providing a free “place like home” that reduces the burdens of illness through a supportive environment that includes therapeutic, educational, and recreational programming for children.

Assembly Biosciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biotherapeutics targeting microbiome-related diseases. The company is advancing a pipeline of drug candidates aimed at improving cure rates for chronic HBV by inhibiting various steps in the viral lifecycle. Its microbiome program features a comprehensive platform for strain identification, isolation, and growth under Good Manufacturing Practices, complemented by a patented delivery system known as GEMICEL, which facilitates targeted oral delivery of therapies to the lower gastrointestinal tract. Key product candidates include ABI-H0731, currently in Phase 2a clinical trials for HBV, and additional candidates under development for conditions such as Crohn’s disease, irritable bowel syndrome, and oncology. Assembly also collaborates with Allergan Pharmaceuticals and Door Pharmaceuticals to enhance its research and development efforts. The company was formerly known as Ventrus Biosciences, Inc. before rebranding in June 2014.

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of targeted and immuno-oncology therapies for cancer treatment. Founded in 2011 and previously known as HealthCare Pharmaceuticals, the company focuses on identifying and developing molecules that inhibit tumor-promoting pathways and activate the immune system against cancer cells. Its lead program, DKN-01, is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1) and is currently undergoing clinical trials for various cancers, including esophagogastric and gynecologic cancers. Additionally, Leap Therapeutics is advancing its second program, FL-301, which targets Claudin18.2-expressing cells, along with two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative treatments for cancer.

SisterLove is a foundation based in Atlanta, Georgia, established in 1989. Its mission is to eradicate the adverse effects of HIV/AIDS and other reproductive health challenges affecting women and their families. SisterLove focuses on education, prevention, support, research, and human rights advocacy, addressing health rights and justice issues both in the United States and globally. The organization seeks to empower women through various initiatives aimed at improving their health outcomes and advocating for their rights.

A New Way of Life Reentry Project is a non profit organization that provides housing and reentry support to formerly incarcerated women and their children. A New Way of Life operates a total of four sober living homes, serving 40-50 women and children per year, and offers a wide range of support services to help facilitate a successful transition back to community life. Since its founding in 1998, A New Way of Life has helped transform the lives of over 220 women.

Transinclusive Group is a Transgender-Led TLGBQ+ tax exempt, non-profit organization. As an advocacy driven organization, its goal is to cultivate advocates to take action to influence social, political, and economic systems to bring about change for all TLGBQ+ individuals.

National Association of Black Social Workers is a non-profit that aims to enhance life and empower people of African ancestry.

Ribbon is a Center of Excellence that specializes in skill-building training and technical assistance, long-term organizational development, and leadership development.

SLK is a community- based health care organization. It promotes the prevention and eradication of illnesses and infections among vulnerable communities, especially high-risk negatives and the LGBTQ community.

Triumphant 2Gether is a tax-exempt, nonprofit organization. It empowers women and girls impacted by violence through policy advocacy and social service projects.

WeCareTn is a non-profit organization build to support transwomen. It supports Transwomen of color through education and empowerment with the goal that they have the same equity and quality of life as envisioned.

Unspoken Treasure Society is a non-profit organization committed to meeting the needs of our TRANS community.

Baltimore Safe Haven provides opportunities for TLGBQ people. They providing housing services and food distributing services for TLGBQ community.

Howard University, located in Washington, D.C., is an esteemed institution established in 1867 that focuses on providing educational opportunities, particularly for African-American students. The university offers a wide range of academic programs at the undergraduate, graduate, and doctoral levels, including fields such as law, medicine, and pharmaceutical studies. With a commitment to fostering high academic achievement and potential, Howard University aims to enhance the educational landscape while reflecting the political and cultural dynamics of its environment.

The California Black Women's Health Project is the only statewide, non-profit organization that is solely committed to ​improving the health of California's 1.2 million Black women and girls through advocacy, education, outreach and policy.

AIDS United is ending the U.S. HIV epidemic through grantmaking, capacity-building, technical assistance, and advocacy.

Dancing Grounds is a nonprofit organization and dance studio with adult fitness and dance classes.

San Francisco Community Health Center is a health organization that focuses on advancing health, wellness, and equality in the community.

PSPRCVA offers a safe haven for Virginia's People of Color - LGBTQ+ community and other marginalised people.

BWLI is a national institute at NDRI-USA Inc., a not-for-profit research and development organization which provides high-impact actionable solutions to pressing public health problems. Its mission is to improve health and wellness for Black women across the lifespan through innovative resources, programmatic support, and culturally-relevant public health education.

WACO (Where Art Can Occur) Theater Center is a cultural institution that promotes modern African Diaspora performing and visual arts.

CymaBay Therapeutics, Inc., established in 1988 and headquartered in Newark, California, is a clinical-stage biopharmaceutical company dedicated to developing therapies for liver diseases and other chronic conditions with significant unmet medical needs. Its primary focus is on seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, currently in Phase II trials for treating primary biliary cholangitis, sclerosing cholangitis, and nonalcoholic steatohepatitis. Additionally, the company is developing MBX-2982, an orally-active G protein-coupled receptor agonist targeting gut/liver diseases, and CB-001, a preclinical-stage product candidate for treating gut/liver disease using omega-3 fatty acids. CymaBay has partnerships with Janssen Pharmaceuticals and DiaTex for developing therapies for metabolic diseases and gout, respectively.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

Hookipa Pharma Inc. is a clinical stage biopharmaceutical company focused on developing innovative immunotherapeutics for infectious diseases and cancers through its proprietary arenavirus platform. The company employs its advanced Vaxwave and TheraT technologies to stimulate robust immune responses, generating antigen-specific killer T cells and antibodies. Hookipa's lead candidate for infectious diseases, HB-101, is currently undergoing a Phase II clinical trial targeting patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, its product candidates HB-201 and HB-202 are in preclinical studies aimed at treating human papillomavirus-positive cancers. Additionally, Hookipa collaborates with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011, the company is headquartered in New York, New York.

Assembly Biosciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biotherapeutics targeting microbiome-related diseases. The company is advancing a pipeline of drug candidates aimed at improving cure rates for chronic HBV by inhibiting various steps in the viral lifecycle. Its microbiome program features a comprehensive platform for strain identification, isolation, and growth under Good Manufacturing Practices, complemented by a patented delivery system known as GEMICEL, which facilitates targeted oral delivery of therapies to the lower gastrointestinal tract. Key product candidates include ABI-H0731, currently in Phase 2a clinical trials for HBV, and additional candidates under development for conditions such as Crohn’s disease, irritable bowel syndrome, and oncology. Assembly also collaborates with Allergan Pharmaceuticals and Door Pharmaceuticals to enhance its research and development efforts. The company was formerly known as Ventrus Biosciences, Inc. before rebranding in June 2014.

Tentarix Biotherapeutics is a company focused on developing innovative protein therapeutics that address critical limitations in the treatment of cancer, autoimmune diseases, and other conditions. Utilizing a protein engineering platform, Tentarix specializes in creating multispecific binding molecules that combine unique bioactivities derived from fully human antibody variable domains. By leveraging synthetic biology, the company aims to provide clinicians with new therapeutic options that offer enhanced specificity and activity, thereby improving patient outcomes in various disease contexts.

Tentarix Biotherapeutics is a company focused on developing innovative protein therapeutics that address critical limitations in the treatment of cancer, autoimmune diseases, and other conditions. Utilizing a protein engineering platform, Tentarix specializes in creating multispecific binding molecules that combine unique bioactivities derived from fully human antibody variable domains. By leveraging synthetic biology, the company aims to provide clinicians with new therapeutic options that offer enhanced specificity and activity, thereby improving patient outcomes in various disease contexts.

Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, the company utilizes advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells that contribute to inflammatory conditions. By addressing the underlying causes of these diseases, Kyverna Therapeutics aims to offer effective solutions for patients suffering from autoimmune disorders.

CDA Foundation is a non-profit organization that specializes in the study of complex and poorly-understood diseases.

XinThera is a drug discovery company dedicated to developing precision medicines for the treatment of cancer and immunologic diseases. The company utilizes advanced computational chemistry technologies to design small molecule therapies aimed at well-validated targets that are often considered challenging in oncology and immunology. By focusing on these promising targets, XinThera strives to provide effective drug therapies that can address unmet medical needs for patients suffering from these conditions.

Compassionate Atlanta is a non-profit organization that offer community building, education, and town planning services in Atlanta.

Alliance of AIDS Services provides health care services. They provide resources and charitable services for AIDS patients. They improve the health of communities impacted by HIV/AIDS through compassionate and non-judgmental prevention, support services, and connection to care.

PCAF provides direct care services to HIV/AIDS patients as well as extensive outreach, education, and prevention programming.

PSPRCVA offers a safe haven for Virginia's People of Color - LGBTQ+ community and other marginalised people.

HEROES supports, educates, and uplifts our community through adult wellness, youth education, and community service.

MBK's objective is to improve the health and well-being of minority and marginalized people across the United States by providing leadership and engagement with the public and community healthcare providers. The HIV prevention services provided by MBK centered on developing and delivering a diverse set of educational and training programs in public health, social policy, action research, information technology, advocacy, coalition development, and capacity building. MBK built its dedication to HIV prevention among racial and ethnic minority communities through its significant expertise, as seen by its service to over 15,000 clients nationwide.

Central Illinois Friends provides compassionate and personalized care to people living with HIV and vulnerable community members who require comprehensive clinical and supportive services.

Transgender Services Empowerment offers dependable services with the goal of empowering the underserved transgender and LGBT communities.

Yale Cancer Center is a cancer treatment center that provides prevention, detection, diagnosis, and treatment for cancer. They provide treatments for patient care,oncology, and hematology.

Nueva vida goal is to educate, encourage, and empower Latinas whose lives are impacted by cancer. Nueva vida also works to promote timely access to cutting-edge cancer treatment.

Young Survival Coalition is engaged in the critical issues unique to young women and breast cancer. They work with survivors, caregivers, medical, research, advocacy, and legislative communities to increase the life expectancy for women diagnosed with breast cancer. They also produce free educational resources, such as the breast cancer navigator series, which are comprehensive guidebooks that address every phase of treatment and survivorship.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. The company's lead product, Viralym-M, targets multiple viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Additionally, AlloVir is advancing several product candidates through preclinical and clinical stages, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. The company, originally founded in 2013 as ViraCyte, Inc., rebranded to AlloVir in May 2019 and is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases.

Exavir Therapeutics is a biotechnology company focused on developing innovative treatments for HIV and other viral infections, as well as central nervous system (CNS) disorders. Operating at the preclinical stage, the company specializes in creating ultra-long-acting nano-medicines designed to provide sustained release of active pharmaceutical ingredients. This approach aims to offer more convenient and effective treatment options for patients with chronic viral infections and CNS disorders.

Curebase is a company that specializes in developing software for clinical trials, aimed at enhancing the efficiency of the clinical research process. Founded in 2017 and based in San Francisco, California, Curebase offers a digital clinical trial assistant that transforms how medical providers discover, activate, and manage clinical trials for patients. The platform reduces recruitment times and automates various manual processes, allowing drug companies to distribute their trials more effectively to clinics. Additionally, it provides comprehensive data access for sponsors, enabling real-time monitoring of trial progress and data management. Curebase serves a diverse clientele, including medical device, biotech, and digital health startups, with a focus on enabling virtual studies and streamlining participant eligibility, enrollment, education, and consent.

Pardes Biosciences is a clinical-stage biopharmaceutical company focused on addressing significant health challenges, particularly those posed by viral infections such as COVID-19. Utilizing modern reversible-covalent chemistry, the company is dedicated to discovering and developing novel oral drug candidates. Its lead product, PBI-0451, is an oral antiviral designed to treat and prevent infections caused by SARS-CoV-2, the virus responsible for COVID-19. Pardes Biosciences aims to enhance patient access to effective treatments, catering to both adult and pediatric populations, while striving to provide convenient and accessible options for those affected by life-threatening viral infections. The company is committed to contributing to global health solutions and improving patient outcomes.

Destination Tomorrow is the Black-led Transgender & Gender Non-Conforming (TGNC) grant-making agency. The Destination Tomorrow offers services that take LGBTQ/TGNC individuals off the path of requiring emergency care with a focus on economic, social and mental empowerment on a holistic level.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

Tango Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, is a biotechnology company focused on developing innovative cancer therapies. The company employs the genetic principle of synthetic lethality to identify and target driver genes in cancer cells. Tango Therapeutics concentrates its efforts on three key areas: counteracting tumor suppressor gene loss, reversing immune evasion by cancer cells, and discovering novel drug combinations for enhanced efficacy. Its pipeline includes TNG908, a precision therapy targeting MTAP-deleted cancers, and several other discovery programs aimed at various cancer types with limited treatment options.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra focuses on creating orally administered dosage forms that provide sustained drug release for extended periods, ranging from a week to a month, while temporarily residing in the stomach. The company aims to address various therapeutic areas, including Alzheimer's, cardiovascular and metabolic diseases, psychiatric disorders, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By developing these innovative therapies, Lyndra seeks to enhance medication adherence, improve health outcomes, and ultimately reduce healthcare costs.

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative immunotherapeutics and vaccines aimed at treating and preventing infectious diseases and cancer. The company utilizes proprietary modified simian adenoviral vectors, specifically ChAdOx1 and ChAdOx2, along with the Modified Vaccinia Ankara (MVA) boost vector, both of which are designed to be safe and non-replicative in humans. This combination approach has demonstrated the ability to generate significantly higher levels of CD8+ T cells compared to other methodologies. Barinthus Biotherapeutics maintains a diverse pipeline that includes both clinical and preclinical therapeutic programs targeting solid tumors, viral infections, and prophylactic viral vaccines. In collaboration with the University of Oxford, the company co-invented a COVID-19 vaccine that has received approval for use in various regions worldwide.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

MYR Group Inc is a U.S.-based holding company that specializes in electrical construction services, primarily through its various subsidiaries. The company operates in two main segments: transmission and distribution, and commercial and industrial. In the transmission and distribution segment, MYR Group provides a range of services that include the design, engineering, procurement, construction, and maintenance of transmission and distribution networks and substation facilities. The commercial and industrial segment focuses on the design, installation, maintenance, and repair of wiring systems, as well as traffic networks and bridges. With a widespread network of local offices across North America, MYR Group is well-equipped to serve the electrical infrastructure market and has established itself as a leader in the industry. The company boasts one of the largest fleets of specialized transmission and distribution equipment in the region, supported by a skilled workforce and an experienced management team.

Immunomedics, Inc. is a clinical-stage biopharmaceutical company based in Morris Plains, New Jersey, that specializes in developing monoclonal antibody-based products for the targeted treatment of cancer. The company is primarily focused on sacituzumab govitecan, an antibody-drug conjugate designed for patients with metastatic triple-negative breast cancer, aiming to position it as a third-line therapy in the United States. Additionally, Immunomedics is engaged in the development of other product candidates, including IMMU-140 for hematologic malignancies and IMMU-130 for colorectal cancer. The company has established clinical collaborations with major pharmaceutical entities to enhance its research and treatment capabilities. Founded in 1982, Immunomedics operates with the goal of delivering innovative therapies to patients with serious diseases. As of October 2020, it functions as a subsidiary of Gilead Sciences, Inc.

Tango Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, is a biotechnology company focused on developing innovative cancer therapies. The company employs the genetic principle of synthetic lethality to identify and target driver genes in cancer cells. Tango Therapeutics concentrates its efforts on three key areas: counteracting tumor suppressor gene loss, reversing immune evasion by cancer cells, and discovering novel drug combinations for enhanced efficacy. Its pipeline includes TNG908, a precision therapy targeting MTAP-deleted cancers, and several other discovery programs aimed at various cancer types with limited treatment options.

Tizona Therapeutics, Inc. is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. Founded in 2014 and based in South San Francisco, California, the company is engaged in creating innovative treatments that target immunosuppressive cells and mechanisms within the tumor microenvironment. Its product pipeline includes an Anti-CCR4 antibody for cancer therapy, as well as IL-35 antagonists and agonists aimed at addressing both cancer and autoimmune conditions. Tizona is also collaborating with its scientific founders to investigate the role of regulatory T cells in various tumors, enhancing the understanding of their contribution to immunosuppression. This research aims to differentiate the company’s approach and improve patient outcomes by facilitating complete and lasting remissions.

Glympse Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing modular nanoparticle sensors for noninvasive diagnostics. Founded in 2015, the company focuses on creating diagnostic solutions for various diseases, including fibrosis, cancer, immunology, and infectious diseases. Utilizing a unique platform technology originally developed at MIT, Glympse Bio employs precisely engineered diagnostic agents that interrogate the body to detect specific disease states and transmit this information to urine for analysis. This innovative approach facilitates predictive monitoring and enhances the ability of physicians to assess treatment responses accurately. The company aims to transform disease monitoring and improve patient outcomes through its Glympse Inside product engine, which supports comprehensive, pan-disease diagnostics.

Goldfinch Bio, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, dedicated to discovering and developing precision therapies for patients with kidney diseases. The company focuses on conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Key product candidates include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio integrates advancements in kidney genetics and biology through its Kidney Genome Atlas, a genomic registry that aids in identifying new disease targets and biomarkers. Additionally, the company employs stem cell science to create human organoid models, which facilitate the validation of novel therapeutic targets. Goldfinch Bio has established a strategic collaboration with Gilead Sciences to further enhance its research and development efforts. Founded in 2016, Goldfinch Bio aims to transform the treatment landscape for progressive kidney disease.

Pionyr Immunotherapeutics Inc. is a biotechnology company focused on developing innovative cancer immunotherapies that specifically target the tumor microenvironment to enhance the body's antitumor immunity. Founded in 2015 and based in San Francisco, California, Pionyr leverages advanced target discovery and antibody generation platform technologies to create next-generation immuno-oncology therapeutics. The company's proprietary approach, known as Myeloid Tuning™, aims to improve the immune system’s anti-tumor response by precisely altering the cellular composition within the tumor microenvironment. This strategy is designed to enable patients to better combat cancer, particularly when used in conjunction with checkpoint inhibitors.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

Forty Seven, Inc. is a clinical-stage immuno-oncology company headquartered in Menlo Park, California, focused on developing innovative therapies to activate macrophages for cancer treatment. The company’s lead product, magrolimab, is a humanized monoclonal antibody targeting the CD47 receptor, which tumors exploit to evade immune detection. Magrolimab is currently undergoing Phase 1b/2 clinical trials for various cancers, including solid tumors and hematologic malignancies such as acute myeloid leukemia and non-Hodgkin's lymphoma. Additionally, Forty Seven is advancing other antibody-based therapies, including FSI-189, which targets SIRPa, and FSI-174, an anti-cKIT antibody. The company collaborates with Genentech and Acerta Pharma to explore further applications of its therapies in combination with other cancer treatments. Founded in 2014 and previously known as CD47 Sciences, Inc., Forty Seven operates as a subsidiary of Gilead Sciences, Inc.

Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.

The National AIDS Memorial relies solely on funding from longtime personal donors and corporate partners to support its mission as a dedicated space in the national landscape where millions of Americans touched directly or indirectly by AIDS can gather to heal, hope, and remember. The National AIDS Memorial, known as “the Grove”, was created more than twenty-eight years ago in San Francisco’s Golden Gate Park at the height of the HIV/AIDS epidemic as a place where those impacted by AIDS could both grieve and begin the process of healing. In 1996, legislation sponsored by U.S. Representative Nancy Pelosi was signed into law by President Clinton that elevated “the Grove” as this nation's sole federally-designated National AIDS Memorial. More than 50,000 individuals from around the world have contributed 225,000 volunteer hours to support the National AIDS Memorial and its mission.

Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, that specializes in the development of innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, Tmunity focuses on harnessing the potential of T cells through novel technologies, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg). The company has developed advanced platforms that allow for precise control over T cell activation and direction in vivo, as well as proprietary methods for activating, expanding, and genetically engineering T cells sourced from peripheral blood, cord blood, and tumors. Tmunity aims to advance personalized next-generation immunotherapies and has a team of experts with extensive experience in T-cell biology and clinical development, enhancing its capability to conduct safe and effective clinical trials. Its robust manufacturing platform supports multi-center clinical studies across various therapeutic areas, positioning Tmunity at the forefront of immunotherapy innovation.

Galapagos NV is a clinical-stage biotechnology company based in Mechelen, Belgium, that focuses on discovering, developing, and commercializing small molecule medicines. The company’s clinical programs include filgotinib, a JAK1 inhibitor undergoing trials for multiple conditions such as rheumatoid arthritis and Crohn’s disease, as well as GLPG1690, an autotaxin inhibitor in trials for idiopathic pulmonary fibrosis and systemic sclerosis. Additionally, Galapagos is developing GLPG1205, a GPR84 inhibitor for idiopathic pulmonary fibrosis, and GLPG1972 for osteoarthritis. The company also explores Toledo molecules for inflammation. Galapagos has established collaborations with several pharmaceutical companies, including Gilead Sciences and AbbVie. Founded in 1999, Galapagos aims to address diseases with high unmet medical needs and improve patient outcomes globally.

AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. The company's lead product, Viralym-M, targets multiple viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Additionally, AlloVir is advancing several product candidates through preclinical and clinical stages, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. The company, originally founded in 2013 as ViraCyte, Inc., rebranded to AlloVir in May 2019 and is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases.

Goldfinch Bio, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, dedicated to discovering and developing precision therapies for patients with kidney diseases. The company focuses on conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Key product candidates include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio integrates advancements in kidney genetics and biology through its Kidney Genome Atlas, a genomic registry that aids in identifying new disease targets and biomarkers. Additionally, the company employs stem cell science to create human organoid models, which facilitate the validation of novel therapeutic targets. Goldfinch Bio has established a strategic collaboration with Gilead Sciences to further enhance its research and development efforts. Founded in 2016, Goldfinch Bio aims to transform the treatment landscape for progressive kidney disease.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra focuses on creating orally administered dosage forms that provide sustained drug release for extended periods, ranging from a week to a month, while temporarily residing in the stomach. The company aims to address various therapeutic areas, including Alzheimer's, cardiovascular and metabolic diseases, psychiatric disorders, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By developing these innovative therapies, Lyndra seeks to enhance medication adherence, improve health outcomes, and ultimately reduce healthcare costs.

Glympse Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing modular nanoparticle sensors for noninvasive diagnostics. Founded in 2015, the company focuses on creating diagnostic solutions for various diseases, including fibrosis, cancer, immunology, and infectious diseases. Utilizing a unique platform technology originally developed at MIT, Glympse Bio employs precisely engineered diagnostic agents that interrogate the body to detect specific disease states and transmit this information to urine for analysis. This innovative approach facilitates predictive monitoring and enhances the ability of physicians to assess treatment responses accurately. The company aims to transform disease monitoring and improve patient outcomes through its Glympse Inside product engine, which supports comprehensive, pan-disease diagnostics.

Precision BioSciences, Inc. is a biotechnology company focused on genome editing, headquartered in Durham, North Carolina. The company utilizes its proprietary ARCUS technology to develop therapeutic products aimed at treating human diseases and improving food and agricultural solutions. Precision BioSciences operates through two segments: Therapeutic and Food. The Therapeutic segment is particularly dedicated to advancing allogeneic CAR T immunotherapies for cancer treatment, including candidates like PBCAR0191 and PBCAR20A, which target specific tumor antigens. The company is also involved in in vivo gene correction and is exploring treatments for conditions such as acute lymphoblastic leukemia and chronic lymphocytic leukemia. Additionally, the Food segment develops innovative nutrition products. Precision BioSciences has formed strategic collaborations, including agreements with Shire Plc and Gilead Sciences, to enhance its research and development capabilities. Founded in 2006, the company aims to harness its next-generation gene editing technology to address pressing health challenges.

Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, that specializes in the development of innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, Tmunity focuses on harnessing the potential of T cells through novel technologies, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg). The company has developed advanced platforms that allow for precise control over T cell activation and direction in vivo, as well as proprietary methods for activating, expanding, and genetically engineering T cells sourced from peripheral blood, cord blood, and tumors. Tmunity aims to advance personalized next-generation immunotherapies and has a team of experts with extensive experience in T-cell biology and clinical development, enhancing its capability to conduct safe and effective clinical trials. Its robust manufacturing platform supports multi-center clinical studies across various therapeutic areas, positioning Tmunity at the forefront of immunotherapy innovation.

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing off-the-shelf, genetically engineered allogeneic T cell therapies for cancer treatment. The company's pipeline includes UCART19, in development for relapsed/refractory acute lymphoblastic leukemia, and several preclinical allogeneic CAR T therapies targeting various cancers. Allogene's approach uses gene editing and advanced manufacturing technologies to create a scalable, broader patient eligibility option compared to autologous therapies. Revenue is primarily generated through collaborations and licensing agreements.

Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, that specializes in the development of innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, Tmunity focuses on harnessing the potential of T cells through novel technologies, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg). The company has developed advanced platforms that allow for precise control over T cell activation and direction in vivo, as well as proprietary methods for activating, expanding, and genetically engineering T cells sourced from peripheral blood, cord blood, and tumors. Tmunity aims to advance personalized next-generation immunotherapies and has a team of experts with extensive experience in T-cell biology and clinical development, enhancing its capability to conduct safe and effective clinical trials. Its robust manufacturing platform supports multi-center clinical studies across various therapeutic areas, positioning Tmunity at the forefront of immunotherapy innovation.

Cell Design Labs, Inc. is a biotherapeutics company based in San Francisco, California, founded in 2015. The company specializes in developing innovative cell-based therapies aimed at treating cancer and other severe diseases. By harnessing the potential of the body's immune system, Cell Design Labs creates advanced therapies that are designed to target and eliminate malignant cells with high precision and safety. Its focus includes developing disruptive T cell receptor therapies that modify immune cells to recognize and destroy cancerous threats effectively. As a subsidiary of Gilead Sciences, Cell Design Labs is positioned to contribute significantly to the field of cancer treatment through its pioneering research and development efforts.

Kite Pharma is a clinical-stage biotechnology company focused on developing innovative immune-based therapies for various cancer indications. The company is dedicated to designing and advancing proprietary product candidates that leverage the patient's immune system to combat tumor cells. By harnessing the potential of cell therapy, Kite Pharma aims to provide effective treatment options and improve the management of a wide range of cancer types, offering new strategies in the fight against this disease.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

EpiTherapeutics is a biotechnology company focused on developing innovative cancer therapies that leverage the science of epigenetics. Founded on research conducted by Professor Kristian Helin and his team at the Biotech Research & Innovation Centre at the University of Copenhagen, the company specializes in small-molecule therapies targeting enzymes that regulate transcription in cancer cells. EpiTherapeutics has created a library of selective small molecule inhibitors, with a particular emphasis on histone demethylases, which play a critical role in gene transcription. The company's lead compounds are currently in pre-clinical development, aimed at addressing specific types of cancer.

Phenex Pharmaceuticals AG is a privately held drug discovery and development company based in Ludwigshafen, Germany, with additional facilities in Heidelberg. Founded in 2002, the company specializes in small-molecule drug discovery, focusing on liver diseases, intestinal diseases, and cancer. Its research includes developing retinoid-acid receptor-related orphan receptor gamma t (RORγt) inverse agonists for autoimmune diseases and farnesoid X receptor (FXR) agonists for non-alcoholic steatohepatitis. Phenex aims to identify novel molecular mechanisms and develop innovative therapeutics, having already translated two such mechanisms into proprietary small molecules.

YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Pharmasset Inc is a clinical-stage pharmaceutical company focused on the discovery and development of innovative drugs for viral infections. The company specializes in oral therapeutics targeting hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Pharmasset's research centers on nucleoside analogs, compounds that inhibit the enzymes necessary for viral replication. Currently, the company's development pipeline includes three key product candidates: Clevudine, which is aimed at treating HBV and is anticipated to enter Phase 3 clinical trials; R7128, a pro-drug designed for the treatment of HCV, currently in Phase 1 trials; and Racivir, an investigational drug for HIV that is undergoing Phase 2 clinical trials. Through these efforts, Pharmasset aims to provide effective treatment options for patients suffering from these viral infections.

Calistoga Pharmaceuticals, Inc. specializes in developing innovative oral medications that target specific isoforms of the PI3 kinase pathway, aiming to enhance the health outcomes of patients suffering from cancer and inflammatory diseases. This critical cellular pathway plays a significant role in cell survival and the activation of immune cells. The company's lead product, CAL-101, is an oral delta-isoform selective PI3K inhibitor that has shown promising clinical responses in patients with B-cell malignancies and is currently under evaluation in various clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals has a robust pipeline of proprietary compounds that selectively inhibit other isoforms of the PI3K pathway, which are in early preclinical development or poised for initial clinical trials targeting cancer and inflammatory conditions.

Arresto Biosciences, Inc., a biotechnology company, develops medicines to treat cancer and fibrotic diseases by targeting molecules from the extracellular matrix. The company was incorporated in 2007 and is based in Palo Alto, California.

CGI Pharmaceuticals, founded in 2000 from Yale University, specializes in the discovery and development of small molecule therapeutics targeting oncology and allergy/autoimmune/inflammatory diseases. The company employs a distinctive chemical-genetics approach known as ASKA (Analog Sensitive Kinase Alleles) to investigate kinase function, collaborating with various biotech and pharmaceutical partners. CGI has developed a proprietary library of over 50,000 small molecule kinase inhibitors, all designed and synthesized in-house. Its comprehensive drug discovery infrastructure includes expertise in kinase biology, chemistry, lead generation, and drug metabolism/pharmacokinetics (DMPK). CGI has been granted eight U.S. patents for its innovative kinase inhibitors, and all of its drug discovery and development programs are derived from candidates identified within its proprietary library. Notable programs focus on Btk, a B-cell kinase for multiple indications, and Syk, which regulates the functions of mast cells, monocytes, macrophages, and B-cells.

CV Therapeutics, Inc. operates as a research-based biopharmaceutical company. The Company researches and manufactures drugs for the treatment of cardiovascular disease and more specifically angina pectoris. CV Therapeutics serves the healthcare industry in the United States. CV Therapeutics developed Ranexa, a drug to treat chronic angina; and Lexiscan, an injection used as a stress agent in cardiovascular procedures. The company was acquired by Gilead Sciences, the maker of H.I.V. drugs Truvada, Viread, and Atriplia, for about $1.4 billion.

Nycomed Limited, formerly known as Altana Pharma Limited. Nycomed Limited has been conducting manufacturing and tabletting operations at the Cork facility.

Raylo Chemicals Inc., a subsidiary of Germany-based specialty chemicals company.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. They believe that our advanced understanding of the biology of cardiovascular disease combined with their clinical development expertise in cardiovascular therapeutics provide us with the capability to discover novel therapies, as well as identify, license or acquire products that address serious, debilitating cardiovascular disorders that are not adequately treated with existing therapies.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Triangle Pharmaceuticals develops new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus.

NeXstar Pharmaceuticals is a Pharmaceutical company.